Our Startups
Enterprise Innovation has launched a diverse portfolio of companies that are based on foundational intellectual property developed in the research laboratories of Weill Cornell Medicine. Our current portfolio of companies encompasses key health-care verticals including diagnostics, digital health, therapeutics, medical devices, and R&D products and services.
Weill Cornell Medicine Startups
MedImageMetric, LLC develops quantitative imaging biomarkers for precision diagnosis and treatment.
Metro Mid-Atlantic Biotech, LLC
Metro Mid-Atlantic Biotech is a development stage startup focused on developing novel small molecule therapeutics based on discoveries in the molecular mechanisms of aging and longevity in mammalian cells.
Mission-Driven Tech is a women’s health venture dedicated to the transformation of gynecologic cancer care with modern technology.
NeuroMedica is developing a revolutionary endovascular flow diverter and coil-containment device for the minimally invasive treatment of bifurcation aneurysms.
Novita Pharmaceuticals, Inc.
Novita Pharmaceuticals, Inc. is a biopharmaceutical startup developing target-specific small molecule drugs to treat cancer metastasis. The company is currently focusing on patients with metastatic breast cancer.
Export control for shipping research and clinical materials is complex and fraught with human error. Onasys leverages industry best practice and regulations to ensure your organization is productive, compliant and safe. Onasys was founded by industry experts at Weill Cornell Medicine and Fitzroy Health.
OneThree Biotech is a VC backed startup developing a biology-driven Artificial Intelligence Technology Platform to accelerate drug discovery and development. The company’s platform enables the health-care and pharmaceutical industry to quickly and accurately generate new testable insights and hypotheses by combing the world of systems and disease biology with computational tools to discover new treatments for patients in need. The platform helps identify novel targets, compounds and new drug combinations, as well as optimizes compounds for toxicity or efficacy.
Pelex is a digital health platform for pelvic floor disorders built on a proprietary connected medical device. The goal of the company is to revolutionize the patient experience by bringing diagnosis and treatment of pelvic floor disorders, such as urinary incontinence and pelvic organ prolapse, out of the clinic and into the home.
Radrite is a non-profit, modern software company that has created the first mobile app for radiology CDSM. This software is inexpensive and easy for clinicians to integrate into their current practice.
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.
Sacyl Pharmaceuticals (SACYL) aims to develop potent soluble adenylyl cyclase (sAC) inhibitors into first-in-class systemic, non-hormonal, on-demand contraceptives for men and women with the goal to significantly contribute to increased use of modern contraceptives among couples to reduce unintended pregnancies, improving families’ health and well-being globally.
Stealth BioTherapeutics, Inc., is a clinical-stage, innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. Their mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need. The company’s first clinical candidate, Bendavia, targets the mitochondria to treat cardio-renal and microvascular impairments.